G1 Therapeutics, Inc. (GTHX)
Stock Price:
$10.99 USD
-0.20 (-1.79%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed
After-hours: $11.50 +0.51 (4.64%) Oct 30, 7:07 PM
Key Info
| Market Cap |
417.78M |
| Revenue (ttm) |
2.14M |
| Net Income (ttm) |
-130.04M |
| Shares Out |
38.01M |
| EPS (ttm) |
-3.45 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 30, 2020 |
| Last Price |
$10.99 |
| Previous Close |
$11.19 |
| Change ($) |
-0.20 |
| Change (%) |
-1.79% |
| Day's Open |
11.14 |
| Day's Range |
10.81 - 11.36 |
| Day's Volume |
655,253 |
| 52-Week Range |
8.80 - 31.38 |
More Stats
| Market Cap |
417.78M |
| Enterprise Value |
210.84M |
| Earnings Date (est) |
Nov 4, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
38.01M |
| Float |
27.97M |
| EPS (basic) |
-3.46 |
| EPS (diluted) |
-3.45 |
| FCF / Share |
-3.00 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
6.85M |
| Short Ratio |
8.55 |
| Short % of Float |
24.50% |
| Beta |
2.05 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
195.22 |
| PB Ratio |
2.36 |
| Revenue |
2.14M |
| Operating Income |
-135.36M |
| Net Income |
-130.04M |
| Free Cash Flow |
-113.33M |
| Net Cash |
206.94M |
| Net Cash / Share |
5.44 |
| Gross Margin |
n/a |
| Operating Margin |
-6,325.19% |
| Profit Margin |
n/a |
| FCF Margin |
-5,295.98% |
| ROA |
-28.45% |
| ROE |
-50.35% |
| ROIC |
-1,338.60% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (8)
| Buy |
8 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$56.86*
(417.38% upside)
Low
24.0
Current: $10.99
High
82.0
Target: 56.86
*Average 12-month price target from 7 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | - | - | - | - | 0.52 |
| Gross Profit | - | - | - | - | 0.52 |
| Operating Income | -129 | -89.29 | -60.97 | -30.39 | -15.42 |
| Net Income | -122 | -85.29 | -60.12 | -30.29 | -20.26 |
| Shares Outstanding | 37.50 | 33.32 | 18.20 | 1.49 | 1.34 |
| Earnings Per Share | -3.27 | -2.56 | -3.57 | -23.33 | -16.13 |
| Operating Cash Flow | -99.57 | -74.31 | -50.52 | -25.14 | -13.85 |
| Capital Expenditures | -2.72 | -0.71 | -0.29 | -0.25 | -0.09 |
| Free Cash Flow | -102 | -75.02 | -50.81 | -25.39 | -13.93 |
| Cash & Equivalents | 270 | 369 | 104 | 47.31 | 22.94 |
| Total Debt | 9.54 | - | - | - | - |
| Net Cash / Debt | 260 | 369 | 104 | 47.31 | 22.94 |
| Assets | 285 | 371 | 105 | 48.21 | 23.90 |
| Liabilities | 29.30 | 12.45 | 11.78 | 5.63 | 55.59 |
| Book Value | 256 | 359 | 93.39 | -64.99 | -31.69 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
G1 Therapeutics, Inc. |
| Country |
United States |
| Employees |
104 |
| CEO |
Mark A. Velleca |
Stock Information
| Ticker Symbol |
GTHX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: GTHX |
| IPO Date |
May 17, 2017 |
Description
G1 Therapeutics, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2 clinical trials for patients with extensive-stage small cell lung cancer(SCLC), as well as Phase 2 clinical trial for patients with first-line (SCLC) and metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase 1b/2a clinical trials for the treatment of breast cancer and in Phase 1b clinical trial for non-small cell lung cancer; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase I/2 clinical trial. G1 Therapeutics, Inc. has a collaboration with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment of locally advanced breast cancer. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.